Breaking News Instant updates and real-time market news.

BIIB

Biogen

$340.67

-2.54 (-0.74%)

20:47
08/13/18
08/13
20:47
08/13/18
20:47

UK's NICE: Biogen's Spinraza too expensive for health service, Reuters reports

U.K.'s National Institute for Health and Care Excellence, or NICE, has ruled that Biogen's muscle disease treatment drug Spinraza, which has a list price of $750K in the first year of treatment, is too expensive for the nation's health service, Reuters reports, citing the agency's statement. NICE director Boysen said that the agency is "actively engaging with Biogen to discuss how they might address the uncertainties identified by the committee, while demonstrating the potential for nusinersen to be considered cost effective and managing the risk to the NHS of allowing access to this treatment." Reference Link

  • 13

    Aug

BIIB Biogen
$340.67

-2.54 (-0.74%)

08/01/18
PIPR
08/01/18
NO CHANGE
Target $400
PIPR
Overweight
Piper recommends Biogen shares after meeting with management
After hosting investor meetings with Biogen investor relations this week, Piper Jaffray analyst Christopher Raymond continues to recommend purchase of the shares. The analyst came away feeling like the "all-important" high-dose APOE4 subset analysis of the BAN2401 results "may be provided sooner than later." If shown to have little impact on the overall placebo-adjusted ADCOMS benefit, this should be an important event, Raymond tells investors in a research note. Coupling this with "continued solid commercial momentum and a host of other value-enhancing catalysts," the analyst continues to like the risk/reward on shares of Biogen. He keeps an Overweight rating on the name with a $400 price target.
08/01/18
08/01/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JEFFERIES UPGRADES DROPBOX TO BUY: Jefferies analyst John DiFucci upgraded Dropbox (DBX) to Buy from Hold with an unchanged price target of $32. The analyst is not making a call on the Q2 results, which come on August 9. Rather, the upgrade is based "entirely on valuation," he stated. Dropbox is up 4.7% in late morning trading. JEFFERIES UPGRADES PAPA JOHN'S: Jefferies analyst Alexander Slagle upgraded Papa John's (PZZA) to Buy from Hold and raised his price target for the shares to $58 from $52. The stock, down 50% from highs, now reflects the likelihood that fundamentals will get worse before improving, Slagle said. After reviewing the company's potential path to recovery and possible strategic actions that could create shareholder value, the analyst has a bull case of $75 per share. He thinks this outweighs the bear case, or downside risk, of $35 per share. SAREPTA UPGRADED AFTER PULLBACK: Morgan Stanley analyst Matthew Harrison upgraded Sarepta Therapeutics (SRPT) to Overweight from Equal Weight, noting that the stock has given up much of the gains it saw when its initial DMD gene therapy data was announced. He sees the pullback as an opportunity to own the stock near pre-DMD gene therapy levels without taking the binary risk. He doesn't think a major bear case has emerged on the prospects for the company's DMD gene therapy program and he sees major catalysts in the second half of this year that he believes the market is missing. Harrison has a $163 price target on Sarepta shares. PIPER CUTS SHOPIFY TO NEUTRAL: Piper Jaffray analyst Michael Olson downgraded Shopify (SHOP) to Neutral from Overweight and lowered his price target to $145 from $155, saying that Shopify's Q2 was "good, but not good enough" with monthly recurring revenue below investor expectations. While Olson said Shopify is performing well, he believes their performance is mostly reflected in the stock's current valuation. PIPER RECOMMENDS BIOGEN AFTER MANAGEMENT MEETING: After hosting investor meetings with Biogen (BIIB) investor relations this week, Piper Jaffray analyst Christopher Raymond came away feeling like the "all-important" high-dose APOE4 subset analysis of the BAN2401 results "may be provided sooner than later." If shown to have little impact on the overall placebo-adjusted ADCOMS benefit, this should be an important event, Raymond said. Coupling this with "continued solid commercial momentum and a host of other value-enhancing catalysts," the analyst continues to like the risk/reward on Biogen. He kept an Overweight rating on shares with a $400 price target.
08/07/18
STFL
08/07/18
INITIATION
Target $394
STFL
Biogen resumed with a Buy at Stifel
Stifel analyst Paul Matteis resumed coverage of Biogen with a Buy rating and a $394 price target, citing his above consensus projections for Spinraza in Spinal Muscular Atrophy and his view that the odds of success for Aducanumab in Alzheimer's are "modestly better than 50/50." While there are real reasons to believe "this time is different" with Aducanumab, Matteis does worry that the floor value in a negative scenario for the Alzheimer's drug might be lower than some think, he tells investors.
08/07/18
STFL
08/07/18
INITIATION
Target $48
STFL
Hold
Ionis Pharmaceuticals transferred with a Hold at Stifel
Stifel transferred coverage of Ionis Pharmaceuticals (IONS) to analyst Paul Matteis, who set a Hold rating and $48 price target on the shares. The Biogen (BIIB) deal, while validating, limits some of the future upside for Ionis, Matteis tells investors. Also, despite his long-term bullishness on the TTR amyloidisis opportunity, he is below consensus for the first year of the launches for Tegsedi and Waylivra.

TODAY'S FREE FLY STORIES

CCJ

Cameco

$9.83

-0.1 (-1.01%)

12:05
09/24/18
09/24
12:05
09/24/18
12:05
Options
Cameco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDV

Andeavor

$158.61

3.81 (2.46%)

, MPC

Marathon Petroleum

$85.71

2.34 (2.81%)

12:02
09/24/18
09/24
12:02
09/24/18
12:02
Hot Stocks
Andeavor, Marathon Petroleum shareholders approve merger »

Stockholders of both…

ANDV

Andeavor

$158.61

3.81 (2.46%)

MPC

Marathon Petroleum

$85.71

2.34 (2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

CMCSA

Comcast

$35.25

-2.66 (-7.02%)

, DIS

Disney

$111.74

1.02 (0.92%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened in negative…

CMCSA

Comcast

$35.25

-2.66 (-7.02%)

DIS

Disney

$111.74

1.02 (0.92%)

FOXA

21st Century Fox

$44.89

0.56 (1.26%)

SKYAY

Sky

$0.00

(0.00%)

P

Pandora

$9.30

0.22 (2.42%)

SIRI

Sirius XM

$6.41

-0.565 (-8.11%)

ABX

Barrick Gold

$11.06

0.58 (5.53%)

GOLD

Randgold

$68.17

4.23 (6.62%)

AMRN

Amarin

$10.11

7.11 (237.00%)

XON

Intrexon

$18.22

3.725 (25.70%)

KORS

Michael Kors

$66.25

-6.42 (-8.83%)

NTNX

Nutanix

$42.93

-3.62 (-7.78%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$44.49

0.52 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 29

    Oct

  • 10

    Dec

VIPS

Vipshop

$6.03

-0.52 (-7.94%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
Hot Stocks
Vipshop falls -8.2% »

Vipshop is down -8.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KORS

Michael Kors

$66.25

-6.42 (-8.83%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
Hot Stocks
Michael Kors falls -8.9% »

Michael Kors is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPDF

PPDAI Group

$6.01

-0.59 (-8.94%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
Hot Stocks
PPDAI Group falls -8.9% »

PPDAI Group is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$45.00

5.47 (13.84%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
Hot Stocks
California Resources rises 13.6% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

SA

Seabridge Gold

$13.10

1.85 (16.44%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
Hot Stocks
Seabridge Gold rises 15.9% »

Seabridge Gold is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

XON

Intrexon

$18.22

3.725 (25.70%)

12:00
09/24/18
09/24
12:00
09/24/18
12:00
Hot Stocks
Intrexon rises 25.4% »

Intrexon is up 25.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,920.36

2.61 (0.14%)

, SIG

Signet Jewelers

$64.47

-2.16 (-3.24%)

11:55
09/24/18
09/24
11:55
09/24/18
11:55
Periodicals
Amazon applies for patent for 'online retail sales of jewelry,' BI reports »

Amazon (AMZN) has applied…

AMZN

Amazon.com

$1,920.36

2.61 (0.14%)

SIG

Signet Jewelers

$64.47

-2.16 (-3.24%)

TIF

Tiffany

$125.58

-1.05 (-0.83%)

DGSE

DGSE Companies

$0.57

(0.00%)

BGI

Birks Group

$1.30

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

BTHE

Boston Therapeutics

$0.00

(0.00%)

11:55
09/24/18
09/24
11:55
09/24/18
11:55
Hot Stocks
Boston Therapeutics starts study of BTI320 on type 2 diabetics on metformin »

Boston Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$150.80

-2.02 (-1.32%)

11:55
09/24/18
09/24
11:55
09/24/18
11:55
Options
Deere put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
09/24/18
09/24
11:55
09/24/18
11:55
Conference/Events
RBC Capital multi-industry analyst to hold group luncheon »

Multi-Industry Analyst…

BSX

Boston Scientific

$38.14

0.38 (1.01%)

11:55
09/24/18
09/24
11:55
09/24/18
11:55
Conference/Events
Boston Scientific to hold an investor event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

11:45
09/24/18
09/24
11:45
09/24/18
11:45
General news
Treasury's $90 B 3- and 6-month bill sale was well received »

Treasury's $90 B 3-…

SPPI

Spectrum

$21.04

-0.33 (-1.54%)

11:44
09/24/18
09/24
11:44
09/24/18
11:44
Hot Stocks
Spectrum announces preliminary poziotinib data from Phase 2 study »

Spectrum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

SNE

Sony

$57.01

-0.025 (-0.04%)

, NTDOY

Nintendo

$0.00

(0.00%)

11:43
09/24/18
09/24
11:43
09/24/18
11:43
Periodicals
Sony to cease manufacturing PlayStation Vita in 2019, BI reports »

According to a recent…

SNE

Sony

$57.01

-0.025 (-0.04%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$9.95

6.95 (231.67%)

11:43
09/24/18
09/24
11:43
09/24/18
11:43
Recommendations
Amarin analyst commentary  »

Citi sees about five…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

RAD

Rite Aid

$1.24

-0.025 (-1.98%)

11:40
09/24/18
09/24
11:40
09/24/18
11:40
Options
10K Rite Aid Jan 1 puts trade for 9c on ISE »

10K Rite Aid Jan 1 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JPM

JPMorgan

$117.18

-0.66 (-0.56%)

11:38
09/24/18
09/24
11:38
09/24/18
11:38
Hot Stocks
JPMorgan's Dimon says hasn't spoken to president since election comments »

JPMorgan CEO Jamie Dimon,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 26

    Sep

  • 28

    Sep

  • 12

    Oct

  • 21

    Oct

  • 26

    Feb

MDT

Medtronic

$98.36

0.51 (0.52%)

11:36
09/24/18
09/24
11:36
09/24/18
11:36
Hot Stocks
Medtronic announces five-year data with CoreValve TAVR system »

Medtronic announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 26

    Sep

  • 09

    Oct

11:35
09/24/18
09/24
11:35
09/24/18
11:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

11:34
09/24/18
09/24
11:34
09/24/18
11:34
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:34
09/24/18
09/24
11:34
09/24/18
11:34
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

ERIC

Ericsson

$8.91

0.12 (1.37%)

11:32
09/24/18
09/24
11:32
09/24/18
11:32
Hot Stocks
Ericsson secures CBRS certification from FCC »

Ericsson announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.